190 related articles for article (PubMed ID: 26813989)
21. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans.
Monsieurs M; Brans B; Bacher K; Dierckx R; Thierens H
Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1581-7. PubMed ID: 12458391
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II clinical trial of high-dose [
Kuroda R; Wakabayashi H; Araki R; Inaki A; Nishimura R; Ikawa Y; Yoshimura K; Murayama T; Imai Y; Funasaka T; Wada T; Kinuya S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1574-1583. PubMed ID: 34837510
[TBL] [Abstract][Full Text] [Related]
23. [131I meta-iodobenzylguanidine in combination with hyperbaric oxygen therapy in the treatment of prognostically high-risk forms of neuroblastoma].
Stanková J; Kavan P; Krízová H; Hermanská E; Dosel P; Sázel M
Cas Lek Cesk; 2001 Jan; 140(1):13-7. PubMed ID: 11242978
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma.
Johnson K; McGlynn B; Saggio J; Baniewicz D; Zhuang H; Maris JM; Mosse YP
Pediatr Blood Cancer; 2011 Dec; 57(7):1124-9. PubMed ID: 21495159
[TBL] [Abstract][Full Text] [Related]
25. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
Mastrangelo S; Tornesello A; Diociaiuti L; Pession A; Prete A; Rufini V; Troncone L; Mastrangelo R
Br J Cancer; 2001 Feb; 84(4):460-4. PubMed ID: 11207038
[TBL] [Abstract][Full Text] [Related]
26. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
Schmidt M; Simon T; Hero B; Eschner W; Dietlein M; Sudbrock F; Bongartz R; Berthold F; Schicha H
Nuklearmedizin; 2006; 45(4):145-51; quiz N39-40. PubMed ID: 16964339
[TBL] [Abstract][Full Text] [Related]
27. Dosimetry-based high-activity therapy with
Genolla J; Rodriguez T; Minguez P; Lopez-Almaraz R; Llorens V; Echebarria A
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1567-1575. PubMed ID: 30838430
[TBL] [Abstract][Full Text] [Related]
28. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation.
Lashford LS; Lewis IJ; Fielding SL; Flower MA; Meller S; Kemshead JT; Ackery D
J Clin Oncol; 1992 Dec; 10(12):1889-96. PubMed ID: 1453204
[TBL] [Abstract][Full Text] [Related]
29. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.
Willegaignon J; Crema KP; Oliveira NC; Pelissoni RA; Coura-Filho GB; Sapienza MT; Buchpiguel CA
Clin Nucl Med; 2018 Aug; 43(8):572-578. PubMed ID: 29916922
[TBL] [Abstract][Full Text] [Related]
30. Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis.
Bleeker G; Schoot RA; Caron HN; de Kraker J; Hoefnagel CA; van Eck BL; Tytgat GA
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1711-7. PubMed ID: 23921531
[TBL] [Abstract][Full Text] [Related]
31. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.
Hoefnagel CA; Rutgers M; Buitenhuis CK; Smets LA; de Kraker J; Meli M; Carrel F; Amstutz H; Schubiger PA; Novak-Hofer I
Eur J Nucl Med; 2001 Mar; 28(3):359-68. PubMed ID: 11315605
[TBL] [Abstract][Full Text] [Related]
32. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.
Castellani MR; Chiti A; Seregni E; Bombardieri E
Q J Nucl Med; 2000 Mar; 44(1):77-87. PubMed ID: 10932604
[TBL] [Abstract][Full Text] [Related]
33. The role of 131I-MIBG in high-risk neuroblastoma treatment.
Lessig MK
J Pediatr Oncol Nurs; 2009; 26(4):208-16. PubMed ID: 19726792
[TBL] [Abstract][Full Text] [Related]
34. Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma.
Howard JP; Maris JM; Kersun LS; Huberty JP; Cheng SC; Hawkins RA; Matthay KK
Pediatr Blood Cancer; 2005 Mar; 44(3):232-9. PubMed ID: 15490487
[TBL] [Abstract][Full Text] [Related]
35. Reaching the target dose with one single
Fiz F; Cirone A; Righi S; Massollo M; Amoroso L; Bottoni G; Conte M; Gambaro M; Massone F; Orengo S; Bruzzone GS; Sorrentino S; Garaventa A; Piccardo A
Pediatr Blood Cancer; 2024 Mar; 71(3):e30806. PubMed ID: 38082548
[TBL] [Abstract][Full Text] [Related]
36. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
Matthay KK; Tan JC; Villablanca JG; Yanik GA; Veatch J; Franc B; Twomey E; Horn B; Reynolds CP; Groshen S; Seeger RC; Maris JM
J Clin Oncol; 2006 Jan; 24(3):500-6. PubMed ID: 16421427
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of
Maric I; Weber M; Prochnow A; Schmitz J; Unger N; Schaarschmidt BM; Poeppel TD; Rischpler C; Bockisch A; Herrmann K; Jentzen W; Fendler WP
J Nucl Med; 2023 Jun; 64(6):885-891. PubMed ID: 36732054
[TBL] [Abstract][Full Text] [Related]
38. Dosimetry for fractionated (131)I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results.
Buckley SE; Saran FH; Gaze MN; Chittenden S; Partridge M; Lancaster D; Pearson A; Flux GD
Cancer Biother Radiopharm; 2007 Feb; 22(1):105-12. PubMed ID: 17627418
[TBL] [Abstract][Full Text] [Related]
39. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma.
DuBois SG; Groshen S; Park JR; Haas-Kogan DA; Yang X; Geier E; Chen E; Giacomini K; Weiss B; Cohn SL; Granger MM; Yanik GA; Hawkins R; Courtier J; Jackson H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Villablanca JG; Marachelian A; Matthay KK
Clin Cancer Res; 2015 Jun; 21(12):2715-21. PubMed ID: 25695691
[TBL] [Abstract][Full Text] [Related]
40. Dosimetric considerations in 131I-MIBG therapy for neuroblastoma in children.
Bolster AA; Hilditch TE; Wheldon TE; Gaze MN; Barrett A
Br J Radiol; 1995 May; 68(809):481-90. PubMed ID: 7788233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
